| AB Science |
| Date/Time | / |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | - |
| Previous Close | - |
| High | - |
| Low | - |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | |
| ISIN | FR0010557264 |
| Security | AB |
| Exchange | Euronext - Paris |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Euronext - P.. | 9.460 |  |
30,155 |
| Cboe Europe .. | 9.53 |  |
2,025 |
| Turquoise | 9.49 | |
895 |
| London Domes.. | 9.635 | |
379 |
| München | 9.605 | |
0 |
| Düsseldorf | 9.445 | |
0 |
| Frankfurt | 9.4600 | |
0 |
| Berlin | 9.470 | |
0 |
| Stuttgart | 9.415 | |
0 |
| Quotrix | 9.5500 | |
|
| Lang & Schwa.. | 9.430 | |
|
| gettex | 9.525 | |
|
| TradeGate | 10.080 | 11 | |
| Nasdaq Other.. | 11.9000 | 180 | |
| Cboe Europe .. | 9.60 | 211 | |
| Cboe Europe .. | 11.07 | 132 |
News
- New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials Landscape
03/01/2022 / 13:55 - GlobeNewswire - AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
02/24/2022 / 18:08 - GlobeNewswire - AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
02/22/2022 / 18:08 - GlobeNewswire - AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
02/21/2022 / 17:48 - GlobeNewswire - AB Science - Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)
02/12/2022 / 20:49 - GlobeNewswire
Real-time